Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of Parkinson's disease

Peter Klivenyi, Gabrielle Gardian, Noel Y. Calingasan, Lichuan Yang, M. Flint Beal

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

There is evidence that both inflammatory mechanisms and mitochondrial dysfunction contribute to Parkinson's disease (PD) pathogenesis. We investigated whether the cyclooxygenase 2 (COX-2) inhibitor rofecoxib either alone or in combination with creatine could exert neuroprotective effects in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine model of PD in mice. Both rofecoxib and creatine administered alone protected against striatal dopamine depletions and loss of substantia nigra tyrosine hydroxylase immunoreactive neurons. Administration of rofecoxib with creatine produced significant additive neuroprotective effects against dopamine depletions. These results suggest that a combination of a COX-2 inhibitor with creatine might be a useful neuroprotective strategy for PD.

Original languageEnglish
Pages (from-to)191-198
Number of pages8
JournalJournal of Molecular Neuroscience
Volume21
Issue number3
DOIs
Publication statusPublished - Dec 1 2003

Keywords

  • Creatine
  • Cyclooxygenase
  • Free radicals
  • Inflammation
  • Mitochondria
  • Parkinson's disease

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this